These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. Miller K; Bergmann L; Gschwend J; Keilholz U Aktuelle Urol; 2011 Jul; 42(4):242-6. PubMed ID: 21720974 [TBL] [Abstract][Full Text] [Related]
44. VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials. Liu F; Chen X; Peng E; Guan W; Li Y; Hu Z; Ye Z; Zhuang Q J Huazhong Univ Sci Technolog Med Sci; 2011 Dec; 31(6):799-806. PubMed ID: 22173502 [TBL] [Abstract][Full Text] [Related]
45. [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus]. de Mulder PH; Haanen JB; Sleijfer S; Kruit WH; Gietema JA; Richel DJ; Groenewegen G; Voest EE; van den Eertwegh AJ; Osanto S; Jansen RL; Mulders PF Ned Tijdschr Geneeskd; 2008 Feb; 152(7):371-5. PubMed ID: 18380383 [TBL] [Abstract][Full Text] [Related]
46. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Gollob JA Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993 [TBL] [Abstract][Full Text] [Related]
47. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389 [TBL] [Abstract][Full Text] [Related]
48. [Renal cell carcinoma management and therapies in 2010]. Albouy B; Gross Goupil M; Escudier B; Massard C Bull Cancer; 2010; 97():17-28. PubMed ID: 20418201 [TBL] [Abstract][Full Text] [Related]
49. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Rini BI Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817 [TBL] [Abstract][Full Text] [Related]
53. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. Heng DY; Xie W; Regan MM; Warren MA; Golshayan AR; Sahi C; Eigl BJ; Ruether JD; Cheng T; North S; Venner P; Knox JJ; Chi KN; Kollmannsberger C; McDermott DF; Oh WK; Atkins MB; Bukowski RM; Rini BI; Choueiri TK J Clin Oncol; 2009 Dec; 27(34):5794-9. PubMed ID: 19826129 [TBL] [Abstract][Full Text] [Related]
54. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Chowdhury S; Larkin JM; Gore ME Eur J Cancer; 2008 Oct; 44(15):2152-61. PubMed ID: 18829302 [TBL] [Abstract][Full Text] [Related]
56. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Escudier B; Michaelson MD; Motzer RJ; Hutson TE; Clark JI; Lim HY; Porfiri E; Zalewski P; Kannourakis G; Staehler M; Tarazi J; Rosbrook B; Cisar L; Hariharan S; Kim S; Rini BI Br J Cancer; 2014 Jun; 110(12):2821-8. PubMed ID: 24823696 [TBL] [Abstract][Full Text] [Related]
57. SU11248 and AG013736: current data and future trials in renal cell carcinoma. Rini BI Clin Genitourin Cancer; 2005 Dec; 4(3):175-80. PubMed ID: 16425985 [TBL] [Abstract][Full Text] [Related]
58. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. Albiges L; Salem M; Rini B; Escudier B Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969 [TBL] [Abstract][Full Text] [Related]
59. Treatment options for metastatic renal cell carcinoma: a review. Athar U; Gentile TC Can J Urol; 2008 Apr; 15(2):3954-66. PubMed ID: 18405442 [TBL] [Abstract][Full Text] [Related]
60. Genetic basis of kidney cancer: a model for developing molecular-targeted therapies. Vira MA; Novakovic KR; Pinto PA; Linehan WM BJU Int; 2007 May; 99(5 Pt B):1223-9. PubMed ID: 17441915 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]